Truist Financial 13F Portfolio

The biggest buys table makes the motive hard to miss: Truist is paying up for growth factor exposure after a drawdown, not chasing whatever just worked. IWF, VUG, and VOO are all meaningfully increased, with IWF up 302.6% and still sitting about -20.1% versus its average cost.

• IWF: A $767.6M add into a growth ETF that is underwater tells you they view the recent underperformance as an entry point, not a warning. This is a high-conviction style call that large-cap growth’s earnings and duration will outrun macro fears.
• VUG and VOO: VUG is boosted by 510.3% (about $456.0M) and VOO by 52.7% (about $410.8M), layering pure growth on top of broad S&P exposure. Together with IVV’s incremental increase, Truist is reinforcing market-cap leadership while tilting the index sleeve toward growthier constituents.
• KLAC and the AI supply chain: The 907.7% surge in KLAC (about $613.9M added) shifts AI exposure from Nvidia’s P&L to the fabs’ capex budgets. KLAC is down roughly -31.9% versus their average buy price, so this is unequivocally averaging down into AI “plumbing”.
• IEMG, IJH, IJR: Adds of $281.8M to IEMG, $51.1M to IJH, and $81.1M to IJR show a parallel bet that growth and re-rating potential sit outside the S&P mega-cap core — in emerging markets and U.S. small/mid caps.

They barely touch core compounders like AAPL, AVGO, LRCX, ABBV, LLY, and JPM, adding incrementally instead. The message: structurally own quality winners, but swing the bat on factor and cycle via ETFs and AI equipment, not by doubling risk in already-stretched single names.

The funding list is almost as telling as the buys. IEFA, RSP, and a cluster of bond and defensive exposures are being trimmed to pay for the growth-and-AI push.

• IEFA: A -15.8% cut (about -$292.5M) in developed ex-US equity is the clearest regional view here. For Truist, Europe and Japan look like dead money relative to U.S. growth and EM upside.
• RSP and SPY: RSP drops -15.1% (about -$103.0M) and SPY is trimmed -2.5% (about -$58.8M) even as IVV and VOO are added. That’s an explicit downgrade of equal-weight and redundant S&P exposure in favor of cap-weighted, growth-heavy indices.
• QQQ and NVDA: QQQ is cut -3.4% (about -$25.1M) and NVDA -1.8% (about -$35.6M). This is not an AI exit; it’s a subtle rebalance away from the most crowded AI proxies into cheaper, underloved parts of the stack like KLAC.
• Bonds and safety: USIG, MBB, AGG all see mid-single-digit percentage trims, and KO is cut -5.8% (about -$70.2M). They’re lightening duration and staple defensives right after both have cushioned returns, which is consistent with a pro-risk, earnings-led stance.

The notable part is what they do not sell: they leave healthcare (ABBV, JNJ, LLY) and high-ROE financials (JPM, BK) largely intact or slightly larger. Those are their ballast; the real “cash register” this quarter is non-U.S. developed equity, equal-weight factor exposure, and some high-multiple AI frontmen.

On the sector chart, the headline looks flat: Technology nudges from 25.41% to 25.31%, and unclassified ETF exposure inches up from 52.32% to 53.24%. The story is in how those unlabeled ETFs reshape the effective factor mix.

Under the “unclassified” bucket, IWF, VUG, XLK, and QQQ collectively push the book more decisively into growth and tech than the raw sector tags show. Equal-weight RSP and value-tilt vehicles like IWD and VTV are trimmed, so even with sector weights stable, factor exposure has clearly moved toward growth and quality over value and size-neutral beta.

Health care creeps up from 4.78% to 4.84% as Truist adds to ABBV, JNJ, and LLY. That’s a quiet but deliberate barbell against their higher-growth, higher-duration tech bets.

Consumer staples and consumer discretionary both drift down — staples from 3.99% to 3.65% via KO, and discretionary from 4.26% to 4.04% via WMT and HD — even though AMZN and TSLA see modest adds. They are effectively trading low-vol consumption for more cyclic, earnings-levered exposure.

Finance and industrials see small net declines, despite adds to JPM, BK, RTX, PWR, and UNP, because the real weight growth is in ETFs. Net-net, Truist ends the quarter more tied to the growth and AI cycle and less to region-specific or style-neutral bets.

Taken together, Truist is positioning for a world where U.S. growth, AI capex, and select EMs keep compounding, while broad developed ex-US and equal-weight factor trades lag. The heavy adds to IWF, VUG, IEMG, and the mid/small-cap sleeves show they want to own the winners of a longer, uneven earnings cycle, not just the last year’s stars.

Their AI stance is maturing. Small trims to NVDA and QQQ, offset by a massive KLAC add and incremental increases in AVGO, LRCX, and ADI, signal a move from AI “narrative” to AI “infrastructure” — from headline chips to the tools and analog guts needed to physically ship that story.

On risk management, the barbell is clear: growth-heavy ETFs and chip equipment on one end, healthcare and high-quality financials on the other, with a thinning layer of staples and broad value in between. The modest pullback in bonds and defensives suggests they see more upside in equities than in duration over the next leg.

If this quarter is a guide, expect future adjustments to continue favoring style and theme vehicles over large single-name swings. Truist seems content to make big calls on what wins — growth, AI capacity, EM and small/mid caps — and let low-cost wrappers and a handful of durable franchises handle the who.